Berkshire Biomedical
Reg CF · Class A-4 Preferred Stock · Feb 2025
ClosedReached targetReg CFPreferred Equityvia StartEngine · last checked Oct 4, 2026View campaign
Raised
$911.5K / $1.5M max
61% of ceiling
Investors
96
$10.6K avg
Post-money valuation
$24.3M
pre-money + amount raised
Financials disclosed in this offering
FY2022–FY2023 · hover for source$266K
−$4.9M
FY2022
$1.7M
−$3.1M
FY2023
RevenueNet income
Metric
FY2022 audited
FY2023 audited
Income statement
Revenue
$266,048
$1,714,007
Cost of goods sold
$0
$0
Gross margin
100%
100%
Net income
-$4,872,643
-$3,142,386
Taxes paid
$0
$0
Balance sheet
Cash
$1,218,839
$89,500
Accounts receivable
$0
$149,650
Total assets
$1,230,874
$252,282
Short-term debt
$708,399
$0
Long-term debt
$5,049,629
$6,502,990
Total liabilities
$5,758,028
$6,502,990
Other
Headcount
—
6
The fiscal years the issuer disclosed in this offering’s filing, as filed. Full history on the company page.
Deal terms
Pre-money$23.3M
Post-money$24.3M
Price / share$8.00
Shares offered2,500
Perks
Early Bird 1: $2,000+ · 10% bonus shares · until Mar 9, 202510% bonus$2K+
Early Bird 2: $5,000+ · 15% bonus shares · until Mar 9, 202515% bonus$5K+
Early Bird 3: $10,000+ · 20% bonus shares · until Mar 9, 202520% bonus$10K+
Early Bird 4: $25,000+ · 25% bonus shares · until Mar 9, 202525% bonus$25K+
Early Bird 5: $50,000+ · 30% bonus shares · until Mar 9, 202530% bonus$50K+
Flash Perk 1: $5,000+ · 10% bonus shares · Mar 30, 2025 – Apr 4, 202510% bonus$5K+
Flash Perk 2: $25,000+ · 15% bonus shares · Mar 30, 2025 – Apr 4, 202515% bonus$25K+
Flash Perk 3: $5,000+ · 5% bonus shares · Apr 24, 2025 – Apr 29, 20255% bonus$5K+
Flash Perk 4: $25,000+ · 10% bonus shares · Apr 24, 2025 – Apr 29, 202510% bonus$25K+
— 10% bonus shares10% bonus$75K+
— 15% bonus shares15% bonus$100K+
Offering details
Target$20,000
Max$1,500,000
Min investment—
OpenedFeb 24, 2025
DeadlineApr 30, 2025
ClosedApr 30, 2025
Days active65
Links & provenance
Source: SEC EDGAR
0001665160-25-000306
Last synced Aug 18, 2026
0001665160-25-000306
Last synced Aug 18, 2026
About this data. Raised amounts and investor counts come from the platform listing and may lag or be restated; SEC-reported totals can differ until the next Form 1-Z/C-U. Post-money valuation is computed as pre-money plus amount raised and is shown once the round closes — it is not a traded price. Financial statements are as reported by the issuer. Crowdonomics is not a broker-dealer, funding portal, or investment adviser; nothing here is investment advice or an offer to sell securities. Verify all figures against the linked EDGAR filings.